| 摘要 |
The present invention relates to pharmaceutical compositions comprising a n NK1 receptor antagonist and a sodium channel blocker compound of formula ( I) wherein R1 and R2 are independently hydrogen, C1-6alkyl or C3-6cycloalkyl C1-6alkyl; or R1 and R2, together with the nitrogen to which they are attach ed, may form an unsubstitued 3-, 4-, 5- or 6-membered saturated ring; R3 is C1-6alkyl, C1-6haloalkyl, C1-3alkoxyC1-3alkyl or C1-3haloalkoxyC1-3alkyl; or R1 and R3, together with the interconnecting atoms, form a saturated or uns aturated 4- to 6-membered ring; X is carbon or nitrogen; n is 0, 1 or 2, whe rein when present each R4 is independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3ha loalkoxy; q is 1 or 2; either R5 or R6 is -O-R7 or -OCH2R7, wherein the othe r R5 or R6 is hydrogen or R4; and wherein R7 is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or m ore nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independe ntly selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1- 3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; or a pharmaceutically accept able salt or solvate thereof; as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatm ent of certain disorders, including epilepsy and mood disorders.
|
